Topic Hub
12 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 12 of 12 clinical reviews.
Tirzepatide (Mounjaro) is being studied for heart failure with preserved ejection fraction (HFpEF). Learn the off-label dosing protocol, trial evidence from SURMOUNT-HFpEF, and what clinicians need to know.
Read clinical reviewA clinical evidence summary of tirzepatide (Mounjaro) for heart failure, including SURMOUNT-HFpEF trial data, mechanism of action, current FDA-approved indications, and what the research means for patients with HFpEF.
Read clinical reviewTirzepatide (Mounjaro) is not FDA-approved for heart failure, but emerging trial data suggest cardiovascular benefits in patients with HFpEF and obesity. Here is what clinicians and patients need to know about off-label use, risks, and tradeoffs.
Read clinical reviewCan Mounjaro (tirzepatide) be used for heart failure? Review the clinical trial data, off-label status, monitoring requirements, and what cardiologists recommend for HFpEF patients.
Read clinical reviewTirzepatide (Mounjaro) is prescribed off-label for PCOS. Review the dosing protocol, clinical evidence for insulin resistance and ovulation, FDA status, and what the research actually shows.
Read clinical reviewTirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging trial data suggest meaningful improvements in ovulation, insulin resistance, and androgen levels. Here is what clinicians and patients should know about the risks and tradeoffs.
Read clinical reviewTirzepatide (Mounjaro) is not FDA-approved for PCOS, but emerging clinical data suggest it may improve insulin resistance, androgen levels, and ovulation in women with polycystic ovary syndrome. Here is what the research says.
Read clinical reviewTirzepatide (Mounjaro) is not FDA-approved for sleep apnea, but clinical trial data from SURMOUNT-OSA show significant AHI reductions. Here's what the evidence actually says about off-label use, risks, and who might benefit.
Read clinical reviewTirzepatide (Mounjaro) is being used off-label for obstructive sleep apnea. Review the SURMOUNT-OSA trial data, dosing protocols, AHI reductions, and what clinicians should know before prescribing.
Read clinical reviewTirzepatide (Mounjaro) is not FDA-approved for sleep apnea, but clinical trial data from SURMOUNT-OSA suggest meaningful reductions in AHI. Here is what the research says about off-label use.
Read clinical reviewTirzepatide (Mounjaro) is FDA-approved for type 2 diabetes but widely prescribed off-label for weight loss. Review the clinical trial data, risks, tradeoffs, and what patients should know.
Read clinical reviewA clinical evidence summary of tirzepatide (Mounjaro) used off-label for weight loss, including trial data from SURMOUNT and SURPASS, dosing, safety, and how it compares to semaglutide.
Read clinical review